{"database": "openregs", "table": "documents", "rows": [["FDA-2019-D-4656-0017", "FDA", "FDA-2019-D-4656", "Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment;\nRevised Draft Guidance for Industry; Availability", "Notice", "Notice of Availability", "2023-06-05T04:00:00Z", 2023, 6, "2023-06-05T04:00:00Z", null, "2023-06-05T15:40:29Z", "2023-11899", 0, 0, "0900006485abbf3a"]], "columns": ["id", "agency_id", "docket_id", "title", "document_type", "subtype", "posted_date", "posted_year", "posted_month", "comment_start_date", "comment_end_date", "last_modified", "fr_doc_num", "open_for_comment", "withdrawn", "object_id"], "primary_keys": ["id"], "primary_key_values": ["FDA-2019-D-4656-0017"], "units": {}, "query_ms": 1.6389850061386824, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}